Mirjam-Collete Kempf, Ph.D., M.P.H., and Michael Saag, M.D., received a $3 million, five-year award to join the Women’s Interagency HIV study (WIHS). Saag is serving as principal investigator at UAB and a sister site at the University of Mississippi Medical Center, and Kempf is co-principal investigator. Recruitment begins at UAB this October.
The WIHS is a longitudinal study that examines how HIV affects the health of women; it is also the longest running study funded by the National Institutes of Health (NIH) for women's health and HIV.
Established in 1993, the WIHS cohort originally had no representation from southern states, despite the heavy HIV disease burdens in the South. Recognizing the need, the NIH approved bringing the study to UAB and its sister site in Jackson, Miss.; Chapel Hill, N.C.; Atlanta, Ga.; and Miami, Fla.
“WIHS is one of the premiere HIV cohorts in the country, and we are very pleased to be a part of it,” said Saag.
For UAB’s cohort, 100 women between the ages 25-60 years old will be needed; 75 of those HIV-positive. Study enrollment will take place at the 1917 Clinic.
Smartphones are learning new tricksYou may think your phone can already do everything, but UAB cybersecurity researchers are adapting accelerometers, GPS chips, gyroscopes and other sensors to make phones that can read your mood, eliminate passwords, protect your bank account and more.Renowned expert named inaugural director of UAB Informatics InstituteJames J. Cimino, M.D., will lead UAB's new Informatics Institute, which was established in June 2014. Cimino, who previously was the chief of the Laboratory for Informatics Development at the NIH Clinical Center and a senior scientist at the National Library of Medicine, is a national leader in the field of biomedical informatics and co-editor of the most influential textbook on the subject.Research enters data-driven eraDuring the past few years, technological innovations have opened up an entirely new way to approach scientific questions. Data-driven research starts with massive information sets — the genomic profiles of thousands of patients, for example, or millions of spam emails — and then searches for emerging patterns in that data. In the latest issue of the U.S. Chamber of Commerce’s "Business Horizon Quarterly", UAB President Ray Watts, M.D., explains the way data-driven research at UAB is being applied to find novel treatments for disease, create new products and businesses and train the next generation of innovation-savvy students.Common blood-pressure drug reverses diabetes in mice, human trials to beginFulbright scholar here to improve health care in Ukraine
Iryna Mazhak, Ph.D., a Fulbright Visiting Scholar from Ukraine, is developing a medical sociology course and textbook materials during her nine months at UAB. No such course or textbook exists in her homeland, she says.How safe are you on the Internet?Participate in a brief, large-scale survey of Internet users that will help UAB researchers design strong authentication systems for securing information privacy.NIH pilot to help move heart-graft technology to market fasterA UAB-led team is one of 24 to receive an inaugural NIH Innovation Corps grant that will enable them to develop a much better understanding of the commercial landscape for a vascular graft technology and significantly refine its plan for bringing it to market.Competition produces creative proposals to reduce obesityNine researchers are halfway to the prize money for their winning entries in the annual Creativity is a Decision Awards. To collect prize money, winners must submit their proposal to an extramural sponsoring authority by Nov. 5.Study to examine how healthy moms pass deadly bacteria to infantsNarayana Sthanam, Ph.D., professor of structural biology, is working to discover how GBS escapes the mother’s natural defense systems in hopes that knowledge will lead to a therapeutic intervention. His research is funded by a $1 million R01 grant from the NIH/NIAID.UAB enrolls nation’s first patient in Phase III drug trial for preeclampsiaIf successful, the drug would be a significant clinical breakthrough for reducing pre-term births and infant mortality.